Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms

Oncogene volume 18, pages 7543–7551 (1999)Cite this article

Abstract

The effects of HIV-1 Tat protein on mitochondria membrane permeability and apoptosis were analysed in lymphoid cells. In this report we show that stable-transfected HIV-Tat cells are primed to undergo apoptosis upon serum withdrawal. This effect was observed in both the Jhan T cell line and the K562 cells, the latter expressing the bcr-abl chimeric gene, which confers resistance to apoptosis induced by different stimuli. Using a cytofluorimetric approach we have determined that serum withdrawal induces a disruption of the transmembrane mitochondrial potential (Δψm) followed by an increase of reactive oxygen species (ROS) and the subsequent DNA nuclear loss in K562-Tat cells but not in the K562-pcDNA cell line. These pre-apoptotic events were associated with the cleavage of the caspase-3, while the expression of Bcl-2, Bcl-XL and Bax proteins was not affected by the presence of Tat. Regardless of the steady state of the Bax protein, we found that in both K562 and K562-Tat cells, this protein is located in the nucleus, but after serum withdrawal its localization was mainly in the cytoplasm. The activity of caspase-3 detected in K562-Tat cells after serum withdrawal paralleled with the mitochondria permeability transition. Nevertheless, in Jhan-Tat cells the inhibition of this caspase with the specific inhibitor, z-DEVD-cmk, did not affect the disruption of the mitochondria potential induced by serum withdrawal. Interestingly, we found that HIV-Tat protein accumulates at the mitochondria in the K562-Tat cells cultured under low serum conditions, and this mitochondrial localization correlated with the Δψm disruption detected in these cells. In addition, HIV-1 Tat protein synergies with protoporphyrin IX (PPIX), a ligand of the mitochondrial benzodiazepine receptor, in the induction of apoptosis in both Jhan and K562 cells. Thus, HIV-1 Tat protein may induce apoptosis by a mechanism that involves mitochondrial PT and may contribute to the lymphocyte depletion seen in AIDS patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Abbreviations

Δψm:

mitochondrial transmembrane potential

DiOC6(3):

3,3′dihexyloxacarbocyanine iodide

HE:

hydroethidine

PI:

propidium iodide

PT:

permeability transition

PPIX:

Protoporphyrin IX

ROS:

reactive oxygen species

References

  • Adams JM and Cory S. . 1998 Science 281: 1322–1326.

  • Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR and Bhalla K. . 1998a Blood 91: 1700–1705.

  • Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DEH, Witte ON and Green DR. . 1998b Oncogene 16: 1383–1390.

  • Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sékaly RP and Finkel TH. . 1992 J. Exp. Med. 176: 1099–1106.

  • Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W and Montagnier L. . 1983 Science 220: 868–871.

  • Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, Simmons DL, Akbar AN, Lord JM and Salmon M. . 1999 Nature 397: 534–539.

  • Costantini P, Chernyak BV, Petronilli V and Bernardi P. . 1996 J. Biol. Chem. 271: 6746–6751.

  • Dalgleish AE, Beverley PCL, Clapham PR, Crawford DH, Greaves MF and Weiss RA. . 1984 Nature 312: 763–767.

  • Dan S, Naito M and Tsuruo T. . 1998 Cell Death Differ. 5: 710–715.

  • Fauci AS. . 1993 Science 262: 1011–1018.

  • Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM and Kupfer A. . 1995 Nature Med. 1: 129–134.

  • Finucane DM, Bossywetzel E, Waterhouse NJ, Cotter TG and Green DR. . 1999 J. Biol. Chem. 274: 2225–2233.

  • France-Lanord V, Brugg B, Michel PP, Agid Y and Ruberg M. . 1997 J. Neurochem. 69: 1612–1621.

  • Gajewski TF and Thompson CB. . 1996 Cell 87: 589–592.

  • Gougeon ML Garcia S, Heeney J, Tschopp R, Lecoeur H, Guetard D, Rame V, Dauguet C and Montagnier L. . 1993 AIDS Res. Hum. Retrov. 9: 553–563.

  • Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoisier M, Goujard C, Debord T and Montagnier L. . 1996 J. Immunol. 156: 3509–3520.

  • Green DR and Reed JC. . 1998 Science 281: 1309–1316.

  • Herbein G, Van Lint C, Lovett JL and Verdin E. . 1998 J. Virol. 72: 660–670.

  • Hirsch T, Marchetti P, Susin SA, Dallaporta B, Zamzami N, Marzo I, Geuskens M and Kroemer G. . 1997 Oncogene 15: 1573–1581.

  • Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M. . 1995 Nature 373: 123–126.

  • Kim CN, Wang XD, Huang Y, Ibrado AM, Liu L, Fang GF and Bhalla K. . 1997 Cancer Res. 57: 3115–3120.

  • Kroemer G. . 1997 Nat. Med. 3: 614–620.

  • Kroemer G, Zamzami N and Susín SA. . 1997 Immunol. Today 18: 44–51.

  • Kruman II, Nath A and Mattson MP. . 1998 Exp. Neurol. 154: 276–288.

  • Lewis DE, Tang DSN, Aduoppong A, Schober W and Rodgers JR. . 1994 J. Immunol. 153: 412–420.

  • Li CJ, Friedman DJ, Wang C, Metelev V and Pardee AB. . 1995 Science 268: 429–431.

  • Liu XS, Zou H, Slaughter C and Wang XD. . 1997 Cell 89: 175–184.

  • Macho A, Blázquez MV, Navas P and Muñoz E. . 1998 Cell Growth Differ. 9: 277–286.

  • Macho A, Castedo M, Marchetti P, Aguilar JJ, Decaudin D, Zamzami N, Girard PM, Uriel J and Kroemer G. . 1995 Blood 86: 2481–2487.

  • Macho A, Hirsch T, Marzo I, Marchetti P, Dallaporta B, Susín SA, Zamzami N and Kroemer G. . 1997 J. Immunol. 158: 4612–4619.

  • Mandal M, Adam L, Mendelsohn J and Kumar R. . 1998 Oncogene 17: 999–1007.

  • Marchetti P, Castedo M, Susín SA, Zamzami N, Hirsch T, Macho A, Haeffner A, Hirsch F, Geuskens M and Kroemer G. . 1996 J. Exp. Med. 184: 1155–1160.

  • Marchetti P, Decaudin D, Macho A, Zamzami N, Hirsch T, Susín, SA and Kroemer G. . 1997 Eur. J. Immunol. 27: 289–296.

  • Marzo I, Brenner C, Zamzami N, Jürgensmeier JM, Susín SA, Vieira HLA, Prévost MC, Xie Z, Matsuyama S, Reed JC and Kroemer G. . 1998 Science 281: 2027–2031.

  • McCloskey TW, Ott M, Tribble E, Khan SA, Teichberg S, Paul MO, Pahwa S, Verdin E and Chirmule N. . 1997 J. Immunol. 158: 1014–1019.

  • McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG and Green DR. . 1995 J. Biol. Chem. 270: 22625–22631.

  • Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RPM and Miedema F. . 1992 Science 257: 217–219.

  • Meyaard L, Otto SA, Keet IP, Roos MT and Miedema F. . 1994 J. Clin. Invest. 93: 982–988.

  • Morana SJ, Wolf CM, Reynolds JE, Brown MK and Eastman A. . 1996 J. Biol. Chem. 271: 18263–18271.

  • Muñoz E, Blazquez MV, Ortiz C, Gomez-Diaz C and Navas P. . 1997 Biochem. J. 325: 23–28.

  • Muro-Cacho CA, Pantaleo G and Fauci AS. . 1995 J. Immunol. 154: 5555–5566.

  • Nishita M, Inoue S, Tsuda M, Tateda C and Miyashita T. . 1998 Exp. Cell Res. 244: 357–366.

  • Patki AH and Lederman MM. . 1996 Cell. Immunol. 169: 40–46.

  • Peña LA, Fuks Z and Kolesnick R. . 1997 Biochem. Pharmacol. 53: 615–621.

  • Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J and Laurent G. . 1997 J. Biol. Chem. 272: 21388–21395.

  • Ray S, Bullock G, Tang C, Ibrado AM, Huang Y and Bhalla K. . 1996 Cell Growth Differ. 7: 1617–1623.

  • Roth J. . 1983 In: Bullock GR and Petrusz P. (eds). Techniques in Immunocytochemistry. Academic Press: London. pp. 217–284.

    Google Scholar 

  • Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T and Calabretta B. . 1998 J. Exp. Med. 187: 1995–2007.

  • Sastry KJ, Marin MC, Nehete PN, McConnell K, el-Naggar AK and McDonnell TJ. . 1996 Oncogene 13: 487–493.

  • Slater AFG, Stefan C, Nobel I, van den Dobbelsteen DJ and Orrenius S. . 1996 Cell Death Differ. 3: 57–62.

  • Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, Fassy F, Reed JC and Kroemer G. . 1997 J. Exp. Med. 186: 25–37.

  • Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M and Kroemer G. . 1996 J. Exp. Med. 184: 1331–1341.

  • Thornberry NA and Lazebnik Y. . 1998 Science 281: 1312–1316.

  • Tuosto L, Montani MSG, Lorenzetti S, Cundari E, Moretti S, Lombardi G and Piccolella E. . 1995 Eur. J. Immunol. 25: 2907–2916.

  • Wadia JS, Chalmers-Redman RME, Ju WJH, Carlie GW, Philips JL, Fraser AD and Tatton WG. . 1998 J. Neurosci. 18: 932–947.

  • Wang HG, Rapp UR and Reed JC. . 1996 Cell 87: 629–638.

  • Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BA, Saag MS and Shaw GM. . 1995 Nature 373: 117–122.

  • Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, Debatin KM and Krammer PH. . 1995a Nature 375: 497–500.

  • Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, Dröge W and Lehmann V. . 1995b EMBO J. 14: 546–554.

  • Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ. . 1997 J. Cell Biol. 139: 1281–1292.

  • Yang J, Liu XS, Bhalla K, Kim CN, Ibrado AM, Cai JY, Peng TI, Jones DP and Wang XD. . 1997 Science 275: 1129–1132.

  • Yang JC and Cortopassi GA. . 1998 Free Radical Biol. Med. 24: 624–631.

  • Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B and Kroemer G. . 1995 J. Exp. Med. 182: 367–377.

  • Zamzami N, Susin SA, Marchetti P, Hirsch T, Gómez-Monterrey I, Castedo M and Kroemer G. . 1996 J. Exp. Med. 183: 1533–1544.

  • Zauli G, Gibellini D, Celeghini C, Mischiati C, Bassini A, La Placa M and Capitani S. . 1996 J. Immunol. 157: 2216–2224.

  • Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ. . 1996 Cell 87: 619–628.

Download references

Acknowledgements

This work was supported by CICYT grant to SAF98-0046 to E Muñoz. The authors wish to thank Ms Carmen Cabrero-Doncel for assistance with the manuscript.

Author information

Authors and Affiliations

  1. Departamento de Fisiología e Inmunología, Universidad de Córdoba, Facultad de Medicina, Avda, de Menéndez Pidal s/n, 14071, Córdoba, Spain

    Antonio Macho, Marco A Calzado, Luis Jiménez-Reina & Eduardo Muñoz

  2. Departamento de Bioquímica y Biología Molecular, Universidad de Cantabria, Spain

    Eva Ceballos & Javier León

Authors
  1. Antonio Macho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco A Calzado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis Jiménez-Reina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eva Ceballos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Javier León
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eduardo Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macho, A., Calzado, M., Jiménez-Reina, L. et al. Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms. Oncogene 18, 7543–7551 (1999). https://doi.org/10.1038/sj.onc.1203095

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203095

Keywords

This article is cited by

Search

Advanced search

Quick links